We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · August 31, 2021

Camrelizumab + Famitinib in Patients With Advanced or Metastatic RCC

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Camrelizumab Plus Famitinib in Patients With Advanced or Metastatic Renal Cell Carcinoma: Data From an Open-Label, Multicenter Phase 2 Basket Study
Clin. Cancer Res 2021 Aug 16;[EPub Ahead of Print], YY Qu, HL Zhang, H Guo, H Luo, Q Zou, N Xing, S Xia, Z Sun, X Zhang, C He, J Cai, X Zhang, Q Wang, DW Ye

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading